PURETECH HEALTH PLC ADR
WKN: A3DB9P | ISIN: US7462371060 | Ticker-Symbol: 0VQ0Siehe auch PURETECH HEALTH PLC
Frankfurt
20.12.24
08:06 Uhr
18,200 Euro
-0,400
-2,15 %
-2,15 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.12. | PureTech's Lung Disease Candidate Slowed Lung Function Decline In Idiopathic Pulmonary Fibrosis Patients | 1 | Benzinga.com | ||
| 16.12. | FTSE 250 movers: Puretech Health rallies; Computacenter says no | 12 | Sharecast | ||
| 16.12. | PureTech's lung fibrosis drug slows decline in phase 2 trial | 3 | FierceBiotech | ||
| 16.12. | PureTech Health plc - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 16.12. | PureTech hails "exciting" results from lung disease trial | 2 | Sharecast | ||
| 16.12. | PureTech's Deupirfenidone Shows Positive Results In Slowing Lung Function Decline In IPF Patients | - | RTTNews | ||
| PURETECH HEALTH PLC ADR Aktie jetzt für 0€ handeln | |||||
| 16.12. | PureTech Health PLC - PRTC's Ph2b in IPF Successful; New SOC Potential | - | RNS | ||
| 11.12. | PureTech Health PLC - PRTC's Seaport Presents Ph1 SPT-300 Data at ACNP | 1 | RNS | ||
| 09.12. | PureTech reports positive LYT-200 trial results in AML/MDS | 4 | Investing.com | ||
| 09.12. | PureTech Health PLC - PRTC Presents LYT-200 Phase 1b Data in AML at ASH | - | RNS | ||
| 20.11. | PureTech Health PLC - PRTC's Seaport Adds Microsoft and J&J Exec to BOD | 4 | RNS | ||
| 05.11. | PureTech Health PLC - PRTC's Seaport Adds Biotech Finance Exec as CFO | 1 | RNS | ||
| 01.11. | PureTech Health PLC - Total Voting Rights | - | RNS | ||
| 31.10. | PureTech Health PLC - Director/PDMR Shareholding | - | RNS | ||
| 30.10. | PureTech Health: PureTech to Present at Two Upcoming Investor Conferences | 170 | Business Wire | PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today... ► Artikel lesen | |
| 30.10. | PureTech Health PLC - PRTC to Present at UBS and Jefferies Conferences | 1 | RNS | ||
| 21.10. | PureTech Health plc - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 21.10. | PureTech thinks the "hub-and-spoke" startup model is still a good bet. If only investors agreed. | 2 | BioPharma Dive | ||
| 21.10. | PureTech Health plc: PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round | 338 | Business Wire | Financing led by General Atlantic with participation from other top tier investors Proceeds will support key clinical milestones in Seaport's pipeline of first and best-in-class neuropsychiatric... ► Artikel lesen | |
| 21.10. | PureTech Health PLC - PRTC's Seaport Closes $225M Series B Financing | 2 | RNS |
Seite:
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 17,400 | -2,68 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| QIAGEN | 42,900 | +0,04 % | Sartorius, Qiagen, Siemens Energy, DHL Group, Adidas, Puma: DAX-Ausblick | Nach seiner jüngsten Rekordjagd hat der DAX in der abgelaufenen Woche etwas Luft geholt. Unter dem Strich legte das größte deutsche Börsenbarometer trotzdem 21 Punkte zu und schloss mit knapp 20.406... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 76,52 | +5,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome | Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,990 | +6,24 % | Arcutis Biotherapeutics, Inc.: Arcutis Submits ZORYVE (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis | ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trialsRoflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile... ► Artikel lesen | |
| EVOTEC | 8,405 | +1,08 % | Evotec Aktie: 50 Prozent hoch oder Ende der Rallye-Träume? | Die Evotec Aktie schloss die vergangene Woche mit einem deutlichen Verlust ab: Fast fünf Prozent Minus am Freitag auf 8,275 Euro zeigen, dass der Druck auf die Biotech-Aktie zunahm. Besonders brisant... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,340 | -0,27 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| CELCUITY | 12,460 | +3,83 % | Celcuity Inc.: Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium | Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months Median OS among patients previously treated with... ► Artikel lesen | |
| CONTINEUM THERAPEUTICS | 13,500 | +1,12 % | Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that... ► Artikel lesen | |
| BIONTECH | 108,60 | +0,09 % | Abstieg und Hoffnung: So steht es um den BioNTech-Konkurrenten Moderna | Die Aktie von Moderna hat in den vergangenen zwölf Monaten eine enttäuschende Entwicklung hingelegt. Im Nasdaq 100 gehört sie in diesem Zeitraum zu den zwei schlechtesten Werten. Nun muss sie den Index... ► Artikel lesen | |
| HUMACYTE | 4,635 | +33,77 % | Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43.
Nvni... ► Artikel lesen | |
| AMGEN | 252,90 | +0,18 % | What's Going On With Amgen Stock On Friday? | ||
| JANUX THERAPEUTICS | 56,70 | -0,09 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| FOGHORN THERAPEUTICS | 5,140 | +3,21 % | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities | Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy... ► Artikel lesen | |
| IMMUNOVANT | 25,880 | +0,86 % | Immunovant (NASDAQ:IMVT) Trading Down 5.2% - Here's Why | ||
| RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen |
PURETECH HEALTH PLC ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -2,15 % bei einem Aktienkurs von 18,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PURETECH HEALTH PLC ADR finden Sie auf Wallstreet Online.
